ILÚM Health Solutions, created by Merck’s Healthcare Services and Solutions division, has announced its acquisition of Teqqa LLC, which provides precision analytics for infectious disease management, according to a press release.
In collaboration with health care providers, ILÚM aims to improve infectious disease outcomes using clinical decision support and electronic patient data, as well assist antimicrobial stewardship programs and sepsis management using technology-based solutions, the release said.
“To achieve our ultimate goal in antibiotic stewardship — to get the right antibiotic to the right patient at the right time — we must embrace the use of technology,” Keith Hamilton, MD, associate health care epidemiologist and director of antimicrobial stewardship at the Hospital of the University of Pennsylvania, which has been working together with Teqqa since 2014, told Infectious Disease News. “Specifically, we need to use technology that brings relevant data and lab results right to the point of care, within the clinician's workflow. These solutions help make sure our clinicians have access to insightful data when it matters most.”
Teqqa has experience working with hospitals to apply disease surveillance solutions and use laboratory and medication data to benefit patients, according to the release. Teqqa’s Precision Antibiotic Therapy analytic, for example, uses patient-specific risk factors from a longitudinal record to help clinicians ensure that the right patients receive the right antibiotics, according to the release.
“We look forward to collaborating with ILÚM to further validate how these solutions support the best possible outcomes for our patients, and we share their commitment to using innovation to fight infectious diseases,” Hamilton said. – by Savannah Demko
Edwards is an employee of ILÚM. Hamilton reports no relevant financial disclosures.